| |
|
|
|
|
|
|
|||
|
Blood, 19 March 2009, Vol. 113, No. 12, pp. 2765-3775. Prepublished online as a Blood First Edition Paper on December 18, 2008; DOI 10.1182/blood-2008-07-168096.
LYMPHOID NEOPLASIA Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome![]() ![]() 1 Departments of Bio-Pathology, Molecular Oncology, Hematology, and Tumor Immunology, Institut Paoli-Calmettes and Université de la Méditerranée, Marseille; 2 Groupe d'Etude des Lymphoproliférations, Centre Henri-Becquerel, Inserm U918, Rouen; 3 Groupe d'Etude des Lymphomes de l'Adulte (GELA), Paris; 4 Department of Pathology and Hematology, Centre Hospitalier and Université de Lille II, Lille; 5 Department of Pathology and Hematology, Centre Hospitalier, Dijon; 6 Department of Pathology and Hematology, Hôtel-Dieu, Paris; and 7 Department of Hematology, Centre Hospitalier, Nancy, France
The outcome of classical Hodgkin lymphoma (cHL) patients may be related to the tumor microenvironment, which in turn may be influenced by Epstein-Barr virus (EBV) infection. To characterize the cHL microenvironment, a set of 63 cHL tissue samples was profiled using DNA microarrays. Their gene expression profile differed from that of histiocyte T cell–rich B-cell lymphoma (H/TCRBCL) samples that were used as controls, mainly due to high expression of PDCD1/PD-1 in H/TCRBCL. EBV+ cHL tissues could be distinguished from EBV– samples by a gene signature characteristic of Th1 and antiviral responses. Samples from cHL patients with favorable outcome overexpressed genes specific for B cells and genes involved in apoptotic pathways. An independent set of 146 cHL samples was analyzed using immunohistochemistry. It showed a significant adverse value in case of high percentage of either TIA-1+-reactive cells or topoisomerase-2+ tumor cells, whereas high numbers of BCL11A+, FOXP3+, or CD20+ reactive cells had a favorable influence. Our results suggest an antitumoral role for B cells in the cHL microenvironment and a stronger stromal influence of the PD1 pathway in H/TCRBCL than cHL. The observation of Th1/ antiviral response in EBV+ cHL tissues provides a basis for novel treatment strategies.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||